SCHEMBL5136609

SCHEMBL5136609

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
ACP1 P24666 1/20 0.38
ACHE P22303 2/20 0.36
KLK7 P49862 1/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 3/20 0.36
TSHR P16473 3/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
HSD11B1 P28845 1/20 0.36
BCHE P06276 3/20 0.35
NPBWR1 P48145 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134835 0.92 C5AR1 (0.44) C5AR1ALDH1A1TSHRKDM4EHSD11B1
SCHEMBL651365 0.90 C5AR1 (0.46) C5AR1ALDH1A1GAATSHRKDM4E
SCHEMBL5136940 0.90 C5AR1 (0.43) C5AR1ALDH1A1GAATSHRKDM4E
SCHEMBL5137466 0.89 DHFR (0.42) C5AR1ACP1ALDH1A1GAATSHR
SCHEMBL5136679 0.89 C5AR1 (0.44) C5AR1ALDH1A1GAATSHRKDM4E
SCHEMBL5072205 0.89 C5AR1 (0.46) C5AR1ALDH1A1GAATSHRKDM4E
SCHEMBL5136840 0.89 C5AR1 (0.41) C5AR1ALDH1A1GAATSHRKDM4E
SCHEMBL5134673 0.89 C5AR1 (0.43) C5AR1ACHEALDH1A1GAATSHR
SCHEMBL5136291 0.88 C5AR1 (0.45) C5AR1ALDH1A1GAATSHRKDM4E
SCHEMBL5136054 0.88 C5AR1 (0.42) C5AR1ALDH1A1GAATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed